Review Article | DOI: https://doi.org/10.31579/2642-973X/177
1Dental Surgeon (DDSc),
-Oncologist (MSc), Specialized in Clinical Oncology, Cytology and Histopathology, Dept. of Pathological Anatomy, Medical School, University of Athens, Athens, Greece.
-Resident in Maxillofacial and Oral Surgery, 401 General Military Hospital of Athens, Athens, Greece.
-PhD in Oncology (cand).
-Registrar in Dentistry, NHS of Greece. Email: nikolaos_c@hotmail.com, nchrysant@med.uoa.gr
2MD, Registrar in Pathology, Ilioupoli Health Centre – NHS of Greece. Athens, Greece.
*Corresponding Author: Nikolaos Andreas Chrysanthakopoulos, Dental Surgeon (DDSc), Oncologist (MSc), Specialized in Clinical Oncology, Cytology and Histopathology, Dept. of Pathological Anatomy, Medical School, University of Athens, Athens, Greece. Resident in Maxillofacial.
Citation: Nikolaos A. Chrysanthakopoulos, Eugenia Kalogiratou, (2026), Microsatellite Instability: Its Role in Carcinogenesis, and in Malignant Brain Neoplasms Development in Adults – A Contemporary Review, J. Brain and Neurological Disorders, 9(3): DOI:10.31579/2642-973X/177.
Copyright: © 2026, Nikolaos Andreas Chrysanthakopoulos. This is an open-access article distributed under the terms of The Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received: 01 April 2026 | Accepted: 15 May 2026 | Published: 05 June 2026
Keywords: microsatellite instability; brain neoplasms; DNA mismatch repair system; molecular biology; genetics
Microsatellite instability (MSI) is a critical molecular event in carcinogenesis and is associated with impaired maintenance of genetic stability. Microsatellites are short, repetitive DNA sequences, e.g., repeated 1-6 base pairs such as, -CACACA - During normal DNA replication, errors may occur in the mentioned regions. Under normal conditions, these errors are corrected by the DNA repair system, which is known as Mis-match Repair (MMR) System. When this system is impaired leads to errors accumulation, which in turn results in MSI. MSI leads to mutations in genes which are responsible for regulation of cell proliferation, DNA repair, and apoptosis (programmed cell death). The mentioned molecular events result in uncontrolled cell growth, accumulation of additional mutations, and eventually, cancer development. Crucial genes which are involved concern defects in MMR genes such as MLH1, MSH2, MSH6, and PMS2, which are frequently associated with Lynch syndrome. MSI is observed mainly in Colorectal Cancer (CRC), especially in proximal colon, Endometrial Cancer (EMC), and less frequently involve Gastric, Ovarian, Small intestine cancer, and certain Urothelial cancers. On the other hand, MSI is not one of the primary mechanisms in most primary malignant brain tumours. However, MSI may be observed in Glioblastomas (GBs), in rare cases, Paediatric tumours with MMR deficiency (dMMR), and tumours in patients with Lynch syndrome (rare CNS involvement), and Turcot syndrome. The presence of MSI has clinical significance as it has major therapeutic implications. To be more specific, MSI-high (MSI-H) tumours have a high mutational burden, and respond better to immunotherapy, eg., PD-1 inhibitors, such as pembrolizumab. The current study presents a contemporary review of modern knowledge regarding the molecular biology of MSI in the development of malignant tumours, and especially in malignant brain tumours in adults.
Microsatellites are short, repetitive DNA sequences that are broadly distributed through-out the genome and are closely associated with many functionally significant genes [1]. Microsatellites, also referred to as simple sequence repeats (SSRs), are repeat units typically consist of one to six nucleotides [2]. Despite their abundance, microsatellites are not randomly distributed. In eukaryotic genomes, they are more frequently localized in non-coding regions than in coding ones, whereas microsatellites located within coding regions are particularly prone to generating frame-shift mutations, thereby contributing to genomic instability and carcinogenesis [3]. Moreover, microsatellites are believed to contribute to the organization and restructuring of chromosomal architecture, thereby influencing gene replication and expression [4], therefore are widely utilized as markers in the study of genetic diseases and as predictive biomarkers across multiple cancer types [5,6]. During DNA replication, microsatellites are particularly susceptible to insertion or deletion errors due to DNA polymerase slippage. Under normal conditions, these errors are associated with the Mismatch Repair (MMR) System [7].
The DNA MMR System plays a critical role in maintaining genomic integrity by identifying and correcting base-pair mismatches that arise during DNA replication, particularly within repetitive sequences such as microsatellites [8]. MMR-associated proteins include at least seven key components, hMLH1, hMLH3, hMSH2, hMSH3, hMSH6, hPMS1, and hPMS2. These proteins form specific heterodimeric complexes that recognize and repair mismatched bases, including small insertion-deletion loops involving one to four nucleotides generated during DNA replication [9]. The MMR pathway is a highly conserved intracellular mechanism involving coordinated interactions among multiple proteins to ensure replication constancy. During DNA replication, errors may occur as a result of recombination events or physical and chemical damage to DNA bases. Under normal conditions, the MMR system detects and corrects these errors. However, mutations or epigenetic alterations in MMR-related genes can impair their function, leading to reduced or absent production of MMR proteins. This deficiency compromises DNA repair capacity and ultimately results in the accumulation of replication errors, leads to variations in microsatellite repeat length giving rise to microsatellite instability (MSI) [10].
MSI is defined as a change in microsatellite length resulting from the insertion or deletion of repeat units, leading to the generation of novel alleles. MSI can arise through various mechanisms, including point mutations in MMR genes, DNA polymerase slippage during replication, and insertion/deletion events within microsatellite regions [11]. Additionally, MSI may result from other molecular aberrations, such as hypermethylation of the MLH1 promoter [12], epigenetic silencing of MSH2 or MLH1 [13,14], microRNA-mediated downregulation of MMR genes [15], or slipped strand mispairing (SSM) [16]. Based on the number of altered microsatellite loci, MSI is classified into three categories, high-level MSI (MSI-H), low-level MSI (MSI-L), and microsatellite stability (MSS) [17]. MSI has been further subclassified into type A (variation <6>8 bp), while another categorization proposed a classification based on fragment size changes into type I (increases) and type II (decreases) [18].
Extensive research has demonstrated that MSI plays a critical role in the development of malignant tumours and is strongly associated with their initiation, progression, and clinical outcomes. Evidence indicates that patients exhibiting MSI-H tend to show enhanced anti-tumour immune responses, greater suppression of tumour cell proliferation, and more favourable prognoses compared to patients with MSI-L or MSS profiles [10,19-21]. According to these criteria, MSI-H is defined by mutations in two or more loci, MSI-L by a mutation in a single locus, and MSS by the absence of detectable mutations [19]. Compared with MSS, MSI status serves as a valuable predictor for therapeutic decision-making, particularly in MSI-H and MSI-L tumours [22]. Historically, the absence of standardized criteria for MSI detection limited progress in this field. To address this the American National Cancer Institute (ANCI), in 1997, proposed a group of five microsatellite markers, BAT25, BAT26, D2S123, D5S346, and D17S250, as reference loci for MSI analysis. Among these, BAT25 and BAT26 were mononucleotide repeats, whereas D2S123, D5S346, and D17S250 were dinucleotide repeats [23]. MSI occurring within the coding regions of genes is referred to as coding MSI (cMSI). This form of instability can result in the inactivation of proteins essential for tumour suppression, as well as the generation of frame shift peptides (FSPs). These FSPs are theoretically novel and tumour-specific antigens, as they arise exclusively from clonal tumour cells and are therefore unrecognized by the host immune system [10].
At present, MSI has been widely identified across a variety of cancers and has emerged as a prominent focus of oncological research. MSI was first identified in CRC cases [24] and subsequently described in other types of cancers. MSI has been associated with the biological behaviour of Colorectal (CR) and gastric carcinoma (GC), lymphoma/leukemia (L/L), and endometrial carcinoma (EMC). The MSI phenotype is frequently associated with Lynch (LS) and Turcot Syndrome (TS), two inherited cancer predisposition syndromes caused by germline mutations in MMR genes [Table1]. LS is most commonly linked to CR and EM cancers but is also associated with malignancies of the ovary, stomach, hepatobiliary tract, upper urinary tract, pancreas, brain, and skin [25-28] [Table 2].
MSI is rare in most primary brain tumours, such as Glioblastoma (GBM) and Anaplastic Astrocytoma (AA), whereas the estimated frequency is less than 5% in gliomas overall [29-33]. However, associations exist in case of genetic syndromes, as MSI is most relevant in brain tumours associated with LS [Table 2]. In these cases, patients may develop high-grade gliomas, whereas tumours often show MMR deficiency and MSI-high status [34]. More recently, MSI has also been detected, even though at lower frequencies, in non-small cell lung cancer (NSCLC), breast cancer (BC), prostate cancer (PC), bladder cancer, and melanoma [35-39] [Table 2].
Furthermore, MSI has been established as an important indicator of treatment response, prognosis, and recurrence in CRC, GC, and other malignancies, highlighting its significance in elucidating the molecular mechanisms underlying carcinogenesis [22,40-42]. Accordingly, MSI represents a promising biomarker for assessing tumour malignancy, therapeutic effectiveness, and patient prognosis. Moreover, characterization of MSI patterns may provide clinicians with valuable insights to support the development of personalized and targeted treatment strategies [40]. The current study presents a contemporary review of modern knowledge regarding the molecular biology of MSI in the development of malignant tumours, and especially in malignant brain tumours in adults.
| Syndrome | Inheritance Mode | Gene/Locus |
Lynch Syndrome (Hereditary Non-Polyposis Colorectal Cancer-HNPCC) |
Autosomal Dominant | MSH2, 2p21, MLH1, 3p21-23 MSH6, 2p21 PMS2, 7p22 (MLH3, 14q24.3) |
Turcot’s Syndrome | Autosomal Dominant or Autosomal Recessive | MLH1, MSH2, MSH6, PMS2 |
Muir-Torre Syndrome (subset of Lynch Syndrome) | Autosomal Dominant | MLH1, MSH2 |
Table 1: Genes causing predisposition to Lunch Syndrome and related Variants
[Modified by Wael M. Abdel-Rahman (2008). Genomic Instability and Carcinogenesis: An Update. Current Genomics; 9: 535-541].
| Diseases | MSI characteristics |
| Lynch Syndrome (LS) | Normal adenocarcinoma, Villous adenoma, Adenoma (over 1.0 cm), Dysplastic adenoma [11] |
| Colorectal Cancer (CRC) | MSI-H tumors (infiltrated with dense cytotoxic T-cells, on the right side) [11] |
| Breast Cancer (BRC) | BRCA1 mutation can cause MSI-MSI related loci D351766 and D252739 can identify MSI related BRC [11] |
| Gastric Cancer (GC) | High expression of CD8 positive T-cell molecular marker, PD-L1 gene and IFN γ gene in patients with MSI-H [11] |
| Prostate Cancer (PC) | MSI frequency less than1.0%, is closely related to pathogenic embryonic mutants carrying Lynch syndrome-related genes [11] |
| Bladder Cancer (BC) | HMSH2 mutation can increase the risk, MSI related loci D9563, D95156, and D95283 can be used to screen patients with high micro-BC [11] |
| Leukemia | MSI frequency less than 1.0%, most are Chronic Myeloid Leukemia [11] |
| Cholangiocarcinoma | MSI frequency less than 1.0%, most are young patients with A typical tissue morphology [11] |
| Ovarian Cancer (OC) | An increased number of CD8+, PD-1, and TILS in MSI OC patients [11] |
| Pancreatic Ductal Adeno-carcinoma (PDAC) | HMLH1 and hMSH2, are mainly inactivated [11] |
| Endometrial Cancer (EC) | UCEC patients with MSI has higher immune com- ponents, CD3+ and CD8+TILS [11] |
| Adrenocortical Cancer (ACC) | MSI-H/dMMR patients with ACC have high variation load, ACC is closely associated with the deletion mutations of hMSH2 [11] |
| Follicular Thyroid Cancer (FTC) | Advanced FTC associated with MMR inactivation [11[ |
| Malignant Brain Tumor | 2.0-3.0% MSI in primary tumors [73,74], Astrocytic and non-Astrocytic CNS tumors showed incidence 0.0-8.0% [29-32], LS-associated account for 0.5-3.7% [147] -25.0% are Glioblastomas [180] |
| Non-Small Cell Lung Cancer (NSCLC) | 0.8-40.0% [131-133] |
| Malignant Melanoma | Frequency 2.0-30.0% [160,161] |
| Urothelial Carcinoma (UC) | Frequency 1.0-28.0% [163-165], LS-associated Upper Tract UC 5.0% [166] |
Table 2: MSI-H/dMMR associated diseases (modified by Li K, et al. (2020). Microsatellite.
Instability: A review of what the oncologist should know. Cancer CellInt; 20: 16)
Mismatch Repair (MMR) System
DNA is continually subjected to stress from both exogenous and endogenous sources. Exogenous factors include environmental and chemical agents such as cigarette smoking, asbestos exposure, and ionizing radiation, while endogenous sources include Reactive Oxygen Species (ROS) and Nitrogen Species (NOS). In addition, DNA sequence variations are able to arise during normal physiological processes such as replication and repair due to the incorrect incorporation of nucleotides. These replication errors are intrinsic to the activity of DNA polymerases [43]. To preserve genomic integrity and prevent the accumulation of deleterious mutations, cells have evolved multiple DNA surveillance and repair mechanisms, among which the MMR system plays a critical role. The MMR system comprises a set of conserved genes encoding proteins that are highly preserved across mammals and humans. Its origin can be traced to studies in Escherichia Coli, where the MutS and MutL genes were first identified as key components of MMR [44]. In humans, the homologous genes implicated in this pathway are referred to as MSH (MutS homologs) and MLH (MutL homologs). The MMR process involves several sequential steps, including lesion recognition, initiation of repair, excision of the damaged DNA segment, and re-synthesis of the correct DNA strand. The MMR system primarily corrects base-base mismatches as well as insertion-deletion loops that occur during DNA replication and recombination. Functional MMR proteins operate as heterodimers, and the system involves multiple gene products, MSH family members such as, hMSH2, hMSH3, and hMSH6 and MLH/PMS family members such as, hMLH1, hPMS1, hMLH3, and hPMS2 [45,46] [Table 3].
In eukaryotic cells, the MMR machinery is primarily organized into two major hetero-dimeric complexes. The first involves hMSH2, which pairs with either hMSH6 or hMSH3 to form the MutSα and MutSβ complexes, respectively. The hMSH2-hMSH6 (MutSα) complex is responsible for recognizing single-base mismatches and small insertion-deletion loops involving dinucleotide repeats, whereas the hMSH2-hMSH3 (MutSβ) complex detects larger insertion-deletion loops, typically up to 13 nucleotides [47]. The MutL homologs in humans belong to the GHKL (gyrase/Hsp90/histidine kinase/ MutL) protein family and function as ATP-dependent molecular complexes capable of forming ring-like structures around the DNA helix. Among these, hMLH1 serves as a central component that forms heterodimers with other partners, including postmeiotic segregation increased (PMS) proteins such as PMS1 and PMS2, as well as MLH3. These complexes are recruited following mismatch recognition by MutSα or MutSβ and play a critical role in co-ordinating downstream repair events [48].
The nature of MSI
Microsatellites, also known as short tandem repeats (STRs) or simple sequence repeats (SSRs), are composed of repetitive DNA sequences consisting of one-six nucleotide motifs [49]. Their distribution differs from that of small satellite DNA, which typically comprises longer tandem repeats of approximately 15-65 nucleotides and is primarily localized near chromosomal termini. In contrast, microsatellites are widely dispersed throughout the genome and are predominantly found in proximity to coding regions, although they may also occur within introns and other non-coding regions. Each micro-satellite locus generally consists of a central repetitive core flanked by peripheral sequences, with its variability largely determined by changes in the number of repeat units with-in the core region [4].
The formation of microsatellites is commonly attributed to DNA polymerase slippage during replication, or to mismatches between the newly synthesized strand and the template strand during DNA replication and repair. These processes can lead to the insertion or deletion of one or more repeat units. Under normal conditions, the DNA MMR system corrects replication errors and maintains genomic stability. However, deficiencies or functional impairments in MMR genes within tumour cells can compromise this repair mechanism, thereby increasing the possibility of genetic mutations [50].
Consequently, MSI is considered a significant factor in tumour initiation and progression. Based on the frequency of instability, MSI is classified into three categories, as already mentioned, MSI-H, MSI-L, and MSS [51], as already mentioned. In current clinical practice, MSI-L is often grouped together with MSS due to their similar biological and clinical characteristics. In CRC, MSI can be further classified according to its underlying molecular mechanisms into sporadic CRC and LS-associated CRC. Most MSI cases are sporadic and arise from epigenetic silencing of gene expression, particularly through hypermethylation of the hMLH1 promoter, rather than direct gene mutations. In contrast, LS is an autosomal dominant hereditary condition caused by germline mutations in MMR genes and is associated with an increased risk of CRC as well as tumours in other regions of the colon and rectum [52].
MSI and Molecular Epidemiology across Cancer Types
The MSI phenotype has been identified across a broad spectrum of malignancies. In a large-scale study analysing over 11,000 tissue samples spanning 39 cancer types, MSI was detected in 27 tumour types, with an overall prevalence of approximately 3.8% [53]. Cancers in which MSI has been reported include CR, G, EM, ovarian, hepatobiliary, urinary tract, brain cancers, and skin malignancies. Among these, the highest prevalence of MSI was observed in CRC (approximately 10.2%, range 6.6-14.5%) [54-59], EMC, particularly the endometrioid subtype, (21.9%, range 15.1-29.6%) [56,60,61], GC (8.5%, range 6.4-10.9%) [55,56,60,62,63], and small bowel cancer (14.3%, range 5.4-26.3%) [56]. In GC, MSI prevalence varies considerably among histological subtypes, ranging from 0.9% in mixed-type tumours and 2.9% in diffuse-type tumours to 10.7% in intestinal-type tumours [63,64]. In contrast, MSI occurs less frequently in other malignancies, with reported rates of approximately 2-10% in ovarian cancer [55,65,66] and only 1-2% in pancreatic cancer [55,67-69]. Estimates of MSI prevalence in urothelial carcinoma remain highly variable, ranging from 1% to as high as 46?ross different studies [70-72]. MSI has also been described in cancers not typically associated with LS, including GBM, cervical cancer, melanoma, sarcoma, and small intestinal tumours. However, its occurrence in these malignancies is relatively rare [55,73,74].
MSI is a hallmark of LS-associated cancers, where it is present in nearly all cases. It is also observed in sporadic cancers, accounting for approximately 10-15% of cases [59]. Nevertheless, LS itself represents a minority of MSI-associated cancers, contributing to no more than 19% of cases. The highest proportion of LS-related MSI is observed in CRC, followed by EMC (5-10%), small bowel cancer (approximately12%), and GC (4-15%) [64,74-77]. Overall, the majority of MSI cases (approximately 80-95%) arise sporadically [78]. The predominant mechanism underlying sporadic MSI is the epigenetic inactivation of the MLH1 gene through promoter hypermethylation, often affecting both alleles and resulting in loss of MLH1 protein expression. This mechanism accounts for approximately 90% of sporadic MSI cases [54,78,79] [Table 2].
Molecular profiling of MSI tumours, regardless of their origin (LS-associated or sporadic), reveals a range of recurrent oncogenic alterations. Frequently observed mutations involve genes such as BRAF, NRAS, KRAS, APC, PIK3CA, and TP53. KRAS mutations are detected in approximately 30-37% of MSI tumours in EM, small bowel, and CR cancers, and in 15-28% of GCs [64,80-82]. Notably, in CRC, the prevalence of KRAS mutations is lower in MSI tumours compared to MSS tutors, where it may reach up to 46% [83]. Furthermore, MSS tutors harbouring KRAS mutations are generally associated with more aggressive tumour behaviour and poorer clinical outcomes [84]. BRAF mutations are frequently observed in MSI CRC, with reported rates of up to 45%, predominantly involving the p.V600E variant [85,86]. Notably, BRAF mutations exhibit a strong association with sporadic cases and are rarely detected in hereditary CRCs [86-89]. In a meta-analysis [90] was demonstrated that the BRAF V600E mutation was present in only approximately 1.4% of patients with LS, underscoring its limited relevance in hereditary MSI-associated tutors. In sporadic CRCs characterized by the MSI phenotype, BRAF p.V600E mutations frequently co-occur with MLH1 promoter hyper-methylation. This association suggests a potential mechanistic link between BRAF activation and epigenetic silencing of MLH1, contributing to the development of MSI in these tutors [91,92].
However, the direct relationship between MLH1 promoter hyper-methylation and the BRAFp.V600E mutation has been questioned by evidence indicating that not all CRCs harbouring BRAFp.V600E exhibit MLH1 silencing or develop the MSI phenotype. A sub-set of these tutors remains MSS, suggesting that additional molecular or epigenetic factors modulate the emergence of MSI in BRAF-mutated cancers [93]. Indeed, only approximately 20-30% of metastatic CRCs carrying the BRAFp. V600E mutation demonstrate MSI [94]. Furthermore, progression to an MSI phenotype through MLH1 hypermethylation is observed in roughly 75% of BRAF-mutated sessile serrated adenomas, while the remaining lesions evolve into MSS tutors. In contrast, among traditional serrated adenomas, BRAF mutations are present in approximately two-thirds of cases. However, MLH1 silencing and MSI are infrequently observed in this subtype [95,96]. Notably, in other cancer types, a consistent association between BRAF p.V 600E mutations and MSI or MMR deficiency (dMMR) has not been established [60-62,97,98].
In comparison, TP53 mutations are significantly less frequent in MSI tutors than in MSS ones. In CR and GC cancers, TP53 mutations are detected in approximately 20-30% of MSI cases, whereas their prevalence in MSS tutors ranges from 50-65% [62,99]. A similar trend is observed in EM, pancreatic, and ovarian cancers, where TP53 mutations are generally common but are rarely identified in MSI-associated tutors [61,67,68,100]. This distribution pattern suggests that TP53 alterations are unlikely to play a critical role in the tumorigenesis of MSI-driven cancers. PIK3CA mutations are more frequently observed in CR and GC cancers with MSI (30-45%) compared with MSS tutors (10-25%). In EMC, however, PIK3CA mutation rates are comparable between MSI and MSS subtypes, comprising approximately 45-60% of cases [61].
MSI tutors are also characterized by recurrent alterations in genes such as PTEN, ATM, RNF43, BRCA2, and ARID1A, all of which demonstrate markedly increased mutation frequencies relative to MSS CRCs [101]. Notably, approximately 20% of MSI tutors harbour therapeutically actionable gene fusions involving ALK, NTRK1/2/3, or RET [101]. In contrast, HER2 amplification does not appear to be significantly associated with MSI status [102].
The interplay between MSI and other oncogenic alterations, as well as the temporal role of dMMR in LS-associated CR carcinogenesis, can be conceptualized within the following distinct models [103]. In the classical model, dMMR arises as a secondary event following adenoma initiation driven by somatic mutations in KRAS and APC genes [104, 105]. Adenomas in this pathway retain MMR proficiency and exhibit MSS status and are most frequently identified in carriers of germline PMS2 or MSH6 mutations [106]. Partial preservation of MMR function in MSH6-deficient tumors, likely due to compensatory activity of MSH3, may underlie the comparatively reduced cancer risk in these individuals [107]. This model is estimated to account for approximately 25% of cases [108,109]. In contrast, the second and third models are characterized by early biallelic inactivation of MMR genes, leading to dMMR as a driver event and consequent MSI in all tumours [104,108]. To be more specific, the second model, predominantly identified in MSH2 and MLH1 mutation carriers, involves frame-shift-mediated inactivation of tumour suppressor genes within the WNT signalling pathway, particularly RNF43 and TGFBR2 [101,109]. The third model, accounting for approximately 10% of LS-associated CRCs and restricted to MLH1 mutation carriers, is defined by concurrent alterations in TP53 and CTNNB1 [104].
Slipped Strand Mispairing
In addition to point mutations, MSI can also arise through slipped strand mispairing (SSM) [110]. During DNA replication and synthesis, misalignment may occur between the newly synthesized strand and the template strand within microsatellite repeat regions. This mispairing can result in transient strand dissociation or the formation of stable looped structures implicating several repeat units. The rate of microsatellite slippage mutations increases exponentially with the number of repeat units [16]. Specifically, microsatellites with shorter repeat tracts tend to undergo expansions more frequently, whereas those with longer repeat tracts are more prone to contraction events.
MMR System Deficiency (dMMR)
MSI phenotype and/or loss of MMR protein expression, also known as deficient MMR (dMMR) phenotype may have tumorigenic potential when occurring in coding regions of key genes involved in several cellular functions and pathways. The MMR system is responsible for correcting errors that arise during DNA replication. In the context of the SSM mechanism mentioned above, aberrant loop structures generated during replication can be recognized and repaired by nucleases and the MMR machinery, restoring the DNA sequence to its pre-replication state. However, in cases of dMMR, these replication errors cannot be properly corrected. As a result, nucleotide substitutions accumulate, and the length of microsatellite sequences becomes altered [10, 111].
MSI-H Cancers and the Role of MSI in Tumorigenesis
A subset of human cancers is characterized by inactivating alterations in MMR genes, resulting in a failure to detect and correct errors that arise during DNA replication. These alterations may be inherited, as observed in LS, or may occur sporadically in approximately 10-15% of CR, G, and EM cancers. Due to their repetitive structure, microsatellite sequences are particularly susceptible to mutations in tumour’s with dMMR function. Consequently, thousands of microsatellite alterations accumulate in the mentioned cancers, which are classified as MSI-H tumours. MSI-H tumours exhibit distinct clinicopathological characteristics compared to MSS cancers, and the spectrum of genetic events driving their progression is thought to differ significantly [112]. Notably, many of the genetic alterations identified in MSI-H tumours involve nucleotide repeat tracts within genes that are believed to have oncogenic potential. These alterations are considered to play a critical role in MSI-H tumorigenesis, as they may result in either gene inactivation or activation and are subject to selection through recessive or dominant mechanisms [113].
Mutation Characteristics in MSI-H Patients
Studies have recorded that MSI-H tumours exhibit certain shared mutational features. For instance, germline mutations in MMR genes, as well as in genes such as POLE (DNA polymerase epsilon) and POLD1 (DNA polymerase delta), are more frequently observed in MSI-H patients compared to those with MSS tumours. Additionally, MSI-H tumours have been reported to enhance oncogene translation by shortening 3′ untranslated regions (3′-UTRs), which may disrupt microRNA (miRNA)-mediated regulatory mechanisms [60]. This phenomenon may help explain findings from a previous report [114], which suggested that certain non-coding RNA molecules resembling pathogenic elements can stimulate immune responses and contribute to tumour progression. These non-coding RNAs, transcribed from satellite DNA, do not encode proteins. However, their regulatory functions are closely associated with tumour development [115].
Association between MSI and tumour mutation burden
Another critical aspect to consider is the association between MSI and tumour mutation burden (TMB). dMMR induces an hypermutator phenotype, resulting in an elevated TMB, which is thought to enhance tumour immunogenicity. While the concurrent presence of MSI and TMB is relatively rare in solid tumours, occurring in only about 3-7% of cases [55,116], this overlap is more pronounced in LS-associated tumours. The incidence of high TMB (TMB-H ≥ 10 mutations / megabase) among MSI tumours is assessed at approximately 80-100% in CRC cases [56,117,118], 83-93% in EMC [56,119-121], and nearly 100% in G and small bowel cancers [56,80,122]. In CRC cases, tumours exhibiting both high TMB and MSI/dMMR correspond to the CMS1 subtype [123]. This subtype is characterized by hypermutation, hypermethylation, BRAF V600E mutations, and robust immune cell infiltration within the tumour microenvironment [124]. In CMS1tumors, MLH1 gene promoter hypermethylation result in gene silencing, DNA mutations accumulation, and the neoantigens expression that contribute to the tumour’s heightened immunogenicity [125]. The TMB levels in MSI tumours may also depend on specific MMR complex loss and tumour histology or its primary site [126,127].
In a recent report which assessed CRC, EMC, and other tumours was found that the loss of mutSα (MSH2/MSH6) typically resulted in a more pronounced TMB than the loss of mutLα (MLH1/PMS2). However, certain tumour histologies, through secondary DNA repair mechanisms, may mitigate the effects of dMMR, leading to a less pronounced TMB despite similar immunohistochemistry (IHC) [Table 3] protein loss patterns. The mentioned findings underscore the gene-and histology-specific heterogeneity of MSI/ dMMR tumours [116]. Importantly, patients with MSI tumours exhibiting a high TMB tend to have a more favourable prognosis and are also considered optimal candidates for check-point inhibitor therapy [125].
MLH1 protein | MSH2 protein | MSH6 protein | PMS2 protein | Interpretation | Inactivated genes |
| + | + | + | + | MSS | None |
| - | + | + | - | MSI | MLH1 |
| + | - | - | + | MSI | MSH2 |
| + | + | - | + | MSI | MSH6 |
| + | + | + | - | MSI | PMS2 |
Table 3: Immunohistochemical patterns of MSI.
(MSI: Microsatellite instability, MSS: Microsatellite Stability).
(Modified by Buecher B, et al. (2013). Role of microsatellite instability in the management of Colorectal cancers. Digest Liv Dis; 45: 441-449).
Mutational Characteristics Across Different Cancers
Analyses based on The Cancer Genome Atlas (TCGA) data indicated that MSI-H tumours shared common mutated loci while also exhibiting tumour-specific mutation standards [128]. For example, genes associated with transmembrane signaling/TGF-β pathways, cellular stress responses/DNA damage, and chromosome/M-phase regulation are frequently enriched among recurrent MSI-related mutations. Frame-shift mutations in TGFBR2 are more commonly observed in colon and gastric adenocarcinoma than in uterine corpus EMC, suggesting that the tumour microenvironment may influence the occurrence of MSI [60].
Furthermore, another study [129] demonstrated that the Promega MSI analysis system, which utilizes a group of five quasi-monomorphic markers (NR-21, BAT-25, MONO-27, NR-24, and BAT-26), can accurately detect MSI-H CRC without the need for matched normal DNA. Another similar report [130] further suggested that MSI tends to occur preferentially within functionally relevant genomic regions. To be more specific, in gastric adenocarcinoma, MSI is frequently associated with genes implicated in ion binding. In addition, tumour suppressor genes such as ACVR2A and RNF were among the most commonly and significantly mutated targets in MSI-H tumors, highlighting their relevance in MSI-driven tumorigenesis [11].
MSI in Other Malignancies
MSI has been identified across a range of malignancies, including non-small cell lung cancer (NSCLC), melanoma, breast cancer (BC), urothelial carcinoma (UC), thyroid cancer (TC), prostate cancer (PC), adrenocortical carcinoma (ACC), cholangiocarcinoma (CC), leukaemia, ovarian cancer (OC), pancreatic ductal adenocarcinoma (PDAC), and primary brain tumours. The expansion of MSI-focused clinical trials to these tumour types may further clarify the prognostic and predictive value of MSI beyond CRC. The reported frequency of MSI in NSCLC cases is highly variable, ranging from 0.8% to 40% [131-133], and its clinical significance in this setting remains incompletely defined. Another study [134] showed that MSI may be associated with poorer prognosis in NSCLC. Conversely, more recent studies indicate that MSI-positive NSCLC may exhibit improved responses to immunotherapy [135], while other clinical trials have demonstrated the efficacy of pembrolizumab in previously treated NSCLC patients harbouring MSI [136,137] [Table 2].
In BC, MSI is relatively rare, with reported frequencies ranging from 0.04% to 3% [138, 139]. However, higher rates have been observed in triple-negative BC (TNBC), where MSI prevalence has been reported to range from approximately 0.2% to 18.6% [140-142]. The clinical and biological significance of MSI in BC remains uncertain. While some studies have reported no significant impact of MSI on overall survival [131], others have suggested a favourable prognostic association, particularly in TNBC [140]. MSI has also been associated with negative expression of estragon and progesterone receptors, suggesting a potential link between microsatellite alterations and hormonal deregulation in BC progression [143]. Additionally, MSI has been associated with advanced clinical stage, larger tumour size, and higher tumour grade [144]. The KEYNOTE-028 and KEYNOTE-012 trials demonstrated the clinical activity of pembrolizumab in BC patients previously treated with CDK4/6 inhibitors [138,145] [Table 2].
PDAC exhibits MSI in approximately 1-2% of cases [146,147], with a subset of MSI-positive tumours associated with LS [148]. LS-associated pancreatic cancers, accounting for approximately 0.5-3.9% of cases, are often characterized by medullary histology and prominent lymphocytic infiltration [147]. Given the aggressive nature of PDAC and its general resistance to chemotherapy, immunotherapy represents a potential therapeutic avenue [149]. Prior studies have shown that patients with proficient (pMMR) PDAC treated with conventional chemotherapy have improved survival compared to those with dMMR tumours, suggesting that MSI status may serve as a predictor of therapeutic response [150-152]. In the KEYNOTE-016 trial, pembrolizumab demonstrated promising activity in MSI-positive PDAC, with complete responses observed in two patients and partial responses in three out of eight cases [73,153]. These findings provide preliminary evidence supporting the potential efficacy of immune checkpoint blockade in MSI-associated PDAC.
MSI has been reported in approximately 10-15% of thyroid cancers (TC) [154-156], and its presence has been associated with specific clinicopathological features. In particular, MSI-positive TCs are more frequently observed in papillary and anaplastic histological subtypes, as well as in poorly differentiated tumours. A recent study suggested that patients with MSI-positive TC may exhibit a more favourable prognosis compared to those with MSS disease [156]. A similar report showed that MSI-H can be detected in TC cases, especially in patients with follicular thyroid cancer (FTC), with a prolonged survival time [157]. It is also considered to be associated with delayed MMR inactivation in advanced TC cases. Although several clinical trials are currently evaluating the efficacy of pembrolizumab, nivolumab, and atezolizumab in MSI-positive TC, no immunotherapy has yet been formally approved for this indication [158,159]. Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis may represent a potential therapeutic option in this context. However, further clinical investigation is required [156] [Table 2].
MSI has also been described in malignant melanoma, with reported frequencies ranging from 2% to 30% [160,161]. Kubeček et al. proposed that MSI may serve as a predictive biomarker in malignant melanoma [162]. Although the KEYNOTE-016 study demonstrated the efficacy of pembrolizumab in MSI-positive melanoma patients who had progressed following prior therapies, MSI-directed immunotherapy is not yet incorporated into routine clinical practice for melanoma [73] [Table 2].
In urothelial carcinoma (UC), MSI has been identified in approximately 1-28% of cases [163-165]. Upper tract UCs (UTUCs) occur in approximately 5% of patients with LS [166]. Loss of the MSH2/MSH6 heterodimer is frequently observed in UTUC, occurring in approximately 50-86% of cases [163,167]. Several studies have reported that MSI-positive UTUCs exhibit distinct morphological features compared to MSS counterparts, including increased intratumoral lymphocytic infiltration, reduced nuclear pleomorphism, and a pushing tumour border [147,168] [Table 2].
In prostate cancer (PC), MSI has been reported in approximately 1.2-12% of cases, and MSI-positive prostate tumours are generally associated with a more aggressive clinical phenotype [169]. Germline mutations in MMR genes are less frequently observed in localized PC, suggesting that MMR alterations may be more common in metastatic disease [170]. The KEYNOTE-016 study demonstrated improved responses to immune checkpoint inhibitors in MSI-positive PC [73]. Although MSI represents a potentially actionable biomarker in PC, immune checkpoint inhibitors are not yet routinely used in the treatment of metastatic disease [171] [Table 2]. Several studies have suggested an association between ACC and MSI. A recent article demonstrated that the occurrence of MSI in ACC is linked to deletion mutations in MSH2 [172]. Additionally, another study reported that MSI-H or dMMR ACC tumours exhibit a high mutational burden [53]. However, there is currently no substantial evidence in the literature regarding the impact of MSI status on the prognosis of ACC [Table 2].
Goeppert et al. [173] identified MSI-H in a small subset of CC cases, particularly in cases not associated with liver fluke infection. MSI-related CC can be detected through analysis of microsatellite loci such as BAT25, BAT26, and CAT25 [173]. Their findings further indicated that MSI-H cases were more frequently observed in younger patients and were associated with atypical histopathological features. Moreover, MSI-H/dMMR CC cases may demonstrate favourable responses to anti–PD-1/PD-L1 immunotherapy [Table 2].
Walker et al. [174] reported that MSI was not detectable in patients with acute myeloid leukaemia (AML). In contrast, Patel et al. [175] identified the presence of MSI in chronic myeloid leukaemia (CML), while no MSI was observed in healthy individuals, suggesting a potential association between MSI and CML pathogenesis. Their study also demonstrated that analysis of microsatellite loci D17S261 and D3S643 may aid in identifying MSI-positive cases of chronic leukaemia. Furthermore, MSI-H/dMMR status in CML cases may be associated with improved outcomes following anti–PD-1/PD-L1 immunotherapy.
A study by Howitt et al. [176] demonstrated that tumours with MSI exhibit increased infiltration of CD8⁺ T cells, PD-1-positive cells, and tumour-infiltrating lymphocytes (TILs). Compared with MSS tumours, patients with clear cell OC characterized by MSI were more likely to benefit from immunotherapy. Furthermore, MSI testing, along with the evaluation of MMR proteins such as hMSH2 and hMSH6, can be utilized to identify MSI-associated OCs [177] [Table 2].
MSI in Brain Malignancies
MSI gliomas appear to occur in a small subset of dMMR extracolonic malignancies. Notably, MSI gliomas may arise in a subset of patients with the rare hereditary condition TS. In a proportion of these patients, germline mutations in MMR genes predispose affected individuals to the concurrent development of MSI-positive CRCs and GBMs [178,179]. The prevalence of MSI in primary brain tumours is relatively low, estimated at approximately 2-3% of cases [73,74]. Brain tumours are only rarely associated with LS, accounting for approximately 0.5-3.7% of cases, and limited data are available regarding the molecular and phenotypic characteristics of LS-associated brain tumours [147]. The MSI phenotype has been reported in approximately 25% of GBM [180] [Table 2]. Notably, MSI-positive GBM is characterized by low PD-L expression, suggesting that PD-L1 may not serve as a reliable predictive biomarker for response to immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway in this tumour type [181].
The MSI phenotype has also been identified in sporadic gliomas in both paediatric and adult populations, although reported frequencies vary considerably. A review of the current literature indicates that, in adult astrocytic and non-astrocytic CNS tumours, MSI was an uncommon event, with an incidence ranging from 0% to 8% [29-32] [Table 2]. However, a higher frequency of MSI has been reported in specific subsets of CNS tumours, particularly WHO grade III and grade IV paediatric astrocytoma’s and gangliogliomas [29,30,182].
Tumour development is a multistep process involving a substantial number of genetic alterations, influenced by both host genetic background and environmental factors. A thorough understanding of these interactions holds significant clinical importance for elucidating tumorigenesis, disease progression, prognosis, and response to chemotherapy. The MMR system is a fundamental DNA repair mechanism responsible for maintaining genomic fidelity and stability. Its inactivation, whether due to germline, somatic, or epigenetic alterations, impairs error correction and promotes the development of MSI. MSI has been identified in multiple cancer types, where it serves both prognostic and predictive roles, particularly in relation to immunotherapy response. MSI is observed across a broad spectrum of cancers, including those associated with Lynch syndrome, such as colorectal, endometrial, small intestinal, and gastric cancers, as well as sporadic tumours, albeit at lower frequencies, such as malignant brain tumours, leukaemias, etc. In this context, the investigation of MSI and frame-shift peptides (FSPs) provides valuable tools for the early molecular screening of high-risk patients and the optimization of therapeutic and personalized target strategies.
Dear Editorial Team, Clinical Medical Reviews and Reports. My experience with the journal was highly positive. The peer-review process was rigorous, constructive, and completed in a timely manner. The reviewers provided valuable comments that helped improve the quality and clarity of our manuscript. The editorial office was professional, responsive, and supportive throughout all stages of the publication process. Communication was clear and efficient, and any questions were addressed promptly. Overall, I found the journal to maintain high scientific standards and an excellent publication workflow. I would be pleased to consider submitting future work to this journal. Best wishes from, Elena Popa.
It was my pleasure to submit my testimonial concerning the Reviewer Board of our Scientific Journal “Brain and Neurological Disorders”. The Reviewers focused on some modifications and their contribution was helpful. The ladies of our Editorial Office were also supported my efforts. It was my honor to have such a co-operation and I am looking forward for more collaboration.
Dear Grace Pierce, Editorial Coordinator of Journal of Clinical Research and Reports, Thank you for the speedy and efficient peer review process. I appreciate the fact that your peer reviewers do not take months to respond like with some other journals. I would also like to thank the editorial office for responding quickly to my questions. It is an excellent journal. I plan to submit more manuscripts in the future. Best wishes from, Robert W. McGee
Dear Grace Pierce, Editorial Coordinator of Journal of Clinical Research and Reports, Working with you and your team on our recent publication in JCRR has been a truly wonderful and enjoyable experience. The responses were prompt, and the reviewers were patient, constructive, and highly professional. One reviewer in particular gave me the feeling that a professor was carefully reading and commenting on my coursework, which was deeply touching. The entire process was straightforward and hassle‑free, with no tedious online forms to complete. I highly recommend this journal. Best wishes from, DR Aibing Rao, Head of R&D
I Appreciate the Opportunity to Share my Experience with the Journal of Clinical Research and Reports. The peer review process was timely and constructive, and the feedback provided helped improve the quality of our manuscript. The editorial office was professional, responsive, and supportive throughout the process, ensuring smooth communication and efficient handling of the submission. Overall, it was a positive experience collaborating with your team.
Dear Mercy Grace, Editorial Coordinator of Obstetrics Gynecology and Reproductive Sciences, We would like to express our gratitude for your help at all stages of publishing and editing the article. The editors of the magazine answer all the necessary questions and help at every stage. We will definitely continue to cooperate and publish other works in the Obstetrics Gynecology and Reproductive Sciences! Best wishes from, Alla Konstantinovna Politova,
Dear Maria Emerson, Editorial Coordinator of International Journal of Clinical Case Reports and Reviews, What distinguishes International Journal of Clinical Case Report and Review is not only the scientific rigor of its publications, but the intellectual climate in which research is evaluated. The submission process is refreshingly free of unnecessary formal barriers and bureaucratic rituals that often complicate academic publishing without adding real value. The peer-review system is demanding yet constructive, guided by genuine scientific dialogue rather than hierarchical or authoritarian attitudes. Reviewers act as collaborators in improving the manuscript, not as gatekeepers imposing arbitrary standards. This journal offers a rare balance: high methodological standards combined with a respectful, transparent, and supportive editorial approach. In an era where publishing can feel more burdensome than research itself, this platform restores the original purpose of peer review — to refine ideas, not to obstruct them Prof. Perlat Kapisyzi, FCCP PULMONOLOGIST AND THORACIC IMAGING.
Dear Reader: We have published several articles in the Auctores Publishing, LLC, journal, Clinical Medical Reviews and Reports in recent years (CMRR). This is an ‘open access’ journal and the following are our observations. From the initial invitation to submit an article, to the final edits of galley proofs, we have found CMRR personnel to be professional, responsive, rapid and thorough. This entire process begins with Catherine Mitchell, Editorial Coordinator. She is simply outstanding, and, I believe, unparalleled in her capacity. I cannot imagine a more responsive and dedicated Editorial Coordinator. As I read the dates and timing of her correspondence with us, it seems that she never sleeps. I hope Auctores Publishing, LLC, appreciates her efforts as much as these authors do. Thank you to Auctores Publishing, LLC, to the Editorial Staff/Board, and to Catherine Mitchell from a grateful author(s).
Dear Maria Emerson, Editorial Coordinator of - Journal of Clinical Research and Reports. ''I am pleased to provide this testimonial following the publication of our recent case report in this journal. The peer review process was rigorous, constructive, thorough, and conducted in a timely manner. The reviewers’ comments were thoughtful, detailed, and highly constructive, contributing substantially to the refinement, clarity, and scientific robustness of our manuscript. The process was conducted with professionalism and academic integrity throughout. The support provided by the editorial office was exemplary. Communication was consistently prompt, clear, and courteous at all stages of the submission and publication process. The editorial team demonstrated a high level of organization and responsiveness, ensuring that all queries were addressed efficiently and that the process remained transparent and well-coordinated. The overall quality of the journal is reflected in its strong editorial standards, commitment to scientific excellence, and dedication to publishing clinically meaningful research. It has been a privilege to publish our work in this journal, and we would welcome the opportunity to contribute further in the future.'' Best wishes from, Dr. Efstratios Trogkanis, Cardiologist.
Dear Grace Pierce, Editorial Coordinator of the journal IJCCR, I had a very positive experience with Auctores - Journal throughout the publication process. The Editorial Team was highly responsive, professional, and supportive at every stage. I would like to extend my sincere thanks to the Editor: Grace Pierce, for her guidance and assistance. The peer-review process was smooth and constructive, helping improve the quality of my work. I would gladly recommend Auctores Journal to fellow researchers and authors. Dr. SABITA SINHA, Medical Oncologist, MD (Electro Homeopathy).
Dear Mayra Duenas, Editorial Coordinator of the journal IJCCR, I write here a little on my experience as an author submitting to the International Journal of Clinical Case Reports and Reviews (IJCCR). This was my first submission to IJCCR and my manuscript was inherently an outsider’s effort. It attempted to broadly identify and then make some sense of life’s under-appreciated mysteries. I initially had responded to a request for possible submissions. I then contacted IJCCR with a tentative topic for a manuscript. They quickly got back with an approval for the submission, but with a particular requirement that it be medically relevant. I then put together a manuscript and submitted it. After the usual back-and-forth over forms and formality, the manuscript was sent off for reviews. Within 2 weeks I got back 4 reviews which were both helpful and also surprising. Surprising in that the topic was somewhat foreign to medical literature. My subsequent updates in response to the reviewer comments went smoothly and in short order I had a series of proofs to evaluate. All in all, the whole publication process seemed outstanding. It was both helpful in terms of the paper’s content and also in terms of its efficient and friendly communications. Thank you all very much. Sincerely, Ted Christopher, Rochester, NY.
International Journal of Clinical Case Reports and Reviews is a high quality journal that has a clear and concise submission process. The peer review process was comprehensive and constructive. Support from the editorial office was excellent, since the administrative staff were responsive. The journal provides a fast and timely publication timeline.
Dear Cecilia Lilly, Editorial Coordinator, Endocrinology and Disorders, Thank you so much for your quick response regarding reviewing and all process till publishing our manuscript entitled: Prevalence of Pre-Diabetes and its Associated Risk Factors Among Nile College Students, Sudan. Best regards, Dr Mamoun Magzoub.
Dear Editorial Team, Clinical Cardiology and Cardiovascular Interventions. I am really grateful for the peers review; their feedback gave me the opportunity to reflect on the message and impact of my work and to ameliorate the article. The editors did a great job in addition by encouraging me to continue with the process of publishing.
Dear Mayra Duenas, Editorial Coordinator of ‘International Journal of Clinical Case Reports and Reviews Herewith I confirm an optimal peer review process and a great support of the editorial office of the present journal
Dear Maria Emerson, Editorial Coordinator of ‘International Journal of Clinical Case Reports and Reviews’, I appreciate the opportunity to publish my article with your journal. The editorial office provided clear communication during the submission and review process, and I found the overall experience professional and constructive. Best regards, Elena Salvatore.
Dear Editorial Team, Journal-Clinical Cardiology and Cardiovascular Interventions, “Publishing my article with Clinical Cardiology and Cardiovascular Interventions has been a highly positive experience. The peer-review process was rigorous yet supportive, offering valuable feedback that strengthened my work. The editorial team demonstrated exceptional professionalism, prompt communication, and a genuine commitment to maintaining the highest scientific standards. I am very pleased with the publication quality and proud to be associated with such a reputable journal.” Warm regards, Dr. Mahmoud Kamal Moustafa Ahmed
Dear Editorial Team, Clinical Cardiology and Cardiovascular Interventions. It was truly a rewarding experience to work with the journal “Clinical Cardiology and Cardiovascular Interventions”. The peer review process was insightful and encouraging, helping us refine our work to a higher standard. The editorial office offered exceptional support with prompt and thoughtful communication. I highly value the journal’s role in promoting scientific advancement and am honored to be part of it. Best regards, Meng-Jou Lee, MD, Department of Anesthesiology, National Taiwan University Hospital.
Dear Maria Emerson, Editorial Coordinator, Journal of Clinical Research and Reports. Thank you for publishing our case report: "Clinical Case of Effective Fetal Stem Cells Treatment in a Patient with Autism Spectrum Disorder" within the "Journal of Clinical Research and Reports" being submitted by the team of EmCell doctors from Kyiv, Ukraine. We much appreciate a professional and transparent peer-review process from Auctores. All research Doctors are so grateful to your Editorial Office and Auctores Publishing support! I amiably wish our article publication maintained a top quality of your International Scientific Journal. My best wishes for a prosperity of the Journal of Clinical Research and Reports. Hope our scientific relationship and cooperation will remain long lasting. Thank you very much indeed. Kind regards, Dr. Andriy Sinelnyk Cell Therapy Center EmCell
I recommend without hesitation submitting relevant papers on medical decision making to the International Journal of Clinical Case Reports and Reviews. I am very grateful to the editorial staff. Maria Emerson was a pleasure to communicate with. The time from submission to publication was an extremely short 3 weeks. The editorial staff submitted the paper to three reviewers. Two of the reviewers commented positively on the value of publishing the paper. The editorial staff quickly recognized the third reviewer’s comments as an unjust attempt to reject the paper. I revised the paper as recommended by the first two reviewers.
Dear Chrystine Mejia, Editorial Coordinator, Journal of Neurodegeneration and Neurorehabilitation. “The peer review process was efficient and constructive, and the editorial office provided excellent communication and support throughout. The journal ensures scientific rigor and high editorial standards, while also offering a smooth and timely publication process. We sincerely appreciate the work of the editorial team in facilitating the dissemination of innovative approaches such as the Bonori Method.” Best regards, Dr. Matteo Bonori.
Dear Maria Emerson, Editorial Coordinator, we have deeply appreciated the professionalism demonstrated by the International Journal of Clinical Case Reports and Reviews. The reviewers have extensive knowledge of our field and have been very efficient and fast in supporting the process. I am really looking forward to further collaboration. Thanks. Best regards, Dr. Claudio Ligresti
Dear Ms. Mayra Duenas, Editorial Coordinator, International Journal of Clinical Case Reports and Reviews. “The International Journal of Clinical Case Reports and Reviews represented the “ideal house” to share with the research community a first experience with the use of the Simeox device for speech rehabilitation. High scientific reputation and attractive website communication were first determinants for the selection of this Journal, and the following submission process exceeded expectations: fast but highly professional peer review, great support by the editorial office, elegant graphic layout. Exactly what a dynamic research team - also composed by allied professionals - needs!" From, Chiara Beccaluva, PT - Italy.
Dear Clarissa Eric, Editorial Coordinator, Journal of Clinical Case Reports and Studies, Auctores Publishing LLC, USA Office: +1-(302)-520-2644. I would like to express my sincere appreciation for the efficient and professional handling of my case report by the ‘Journal of Clinical Case Reports and Studies’. The peer review process was not only fast but also highly constructive—the reviewers’ comments were clear, relevant, and greatly helped me improve the quality and clarity of my manuscript. I also received excellent support from the editorial office throughout the process. Communication was smooth and timely, and I felt well guided at every stage, from submission to publication. The overall quality and rigor of the journal are truly commendable. I am pleased to have published my work with Journal of Clinical Case Reports and Studies, and I look forward to future opportunities for collaboration. Sincerely, Aline Tollet, UCLouvain.
Dear Chrystine Mejia, Editorial Coordinator, Journal of Neurodegeneration and Neurorehabilitation, Auctores Publishing LLC, We would like to thank the editorial team for the smooth and high-quality communication leading up to the publication of our article in the Journal of Neurodegeneration and Neurorehabilitation. The reviewers have extensive knowledge in the field, and their relevant questions helped to add value to our publication. Kind regards, Dr. Ravi Shrivastava.
Dear Clarissa Eric, Editorial Coordinator, Journal of Clinical Case Reports and Studies, I would like to express my deep admiration for the exceptional professionalism demonstrated by your journal. I am thoroughly impressed by the speed of the editorial process, the substantive and insightful reviews, and the meticulous preparation of the manuscript for publication. Additionally, I greatly appreciate the courteous and immediate responses from your editorial office to all my inquiries. Best Regards, Dariusz Ziora
Dear Ashley Rosa, Editorial Coordinator, International Journal of Clinical Case Reports and Reviews, Auctores Publishing LLC. Thank you for publishing our article, Exploring Clozapine's Efficacy in Managing Aggression: A Multiple Single-Case Study in Forensic Psychiatry in the international journal of clinical case reports and reviews. We found the peer review process very professional and efficient. The comments were constructive, and the whole process was efficient. On behalf of the co-authors, I would like to thank you for publishing this article. With regards, Dr. Jelle R. Lettinga.
Dear Jessica Magne, Editorial Coordinator, Clinical Cardiology and Cardiovascular Interventions, Auctores Publishing LLC. The peer review process of the journal of Clinical Cardiology and Cardiovascular Interventions was excellent and fast, as was the support of the editorial office and the quality of the journal. Kind regards Walter F. Riesen Prof. Dr. Dr. h.c. Walter F. Riesen.
Dear Erin Aust, Editorial Coordinator, Journal of General Medicine and Clinical Practice. We are pleased to share our experience with the “Journal of General Medicine and Clinical Practice”, following the successful publication of our article. The peer review process was thorough and constructive, helping to improve the clarity and quality of the manuscript. We are especially thankful to Ms. Erin Aust, the Editorial Coordinator, for her prompt communication and continuous support throughout the process. Her professionalism ensured a smooth and efficient publication experience. The journal upholds high editorial standards, and we highly recommend it to fellow researchers seeking a credible platform for their work. Best wishes By, Dr. Rakhi Mishra.
Dr Hala Al Shaikh This is to acknowledge that the peer review process for the article ’ A Novel Gnrh1 Gene Mutation in Four Omani Male Siblings, Presentation and Management ’ sent to the International Journal of Clinical Case Reports and Reviews was quick and smooth. The editorial office was prompt with easy communication.
Dear Agrippa Hilda, Editorial Coordinator, Journal of Neuroscience and Neurological Surgery. The entire process including article submission, review, revision, and publication was extremely easy. The journal editor was prompt and helpful, and the reviewers contributed to the quality of the paper. Thank you so much! Eric Nussbaum, MD
Dear Ashley Rosa, Editorial Coordinator, International Journal of Clinical Case Reports and Reviews. Many thanks for publishing this manuscript after I lost confidence the editors were most helpful, more than other journals Best wishes from, Susan Anne Smith, PhD. Australian Breastfeeding Association.
Dear Maria Emerson, Editorial Coordinator, International Journal of Clinical Case Reports and Reviews, Auctores Publishing LLC. I am delighted to have published our manuscript, "Acute Colonic Pseudo-Obstruction (ACPO): A rare but serious complication following caesarean section." I want to thank the editorial team, especially Maria Emerson, for their prompt review of the manuscript, quick responses to queries, and overall support. Yours sincerely Dr. Victor Olagundoye.
Dear Jessica Magne, Editorial Coordinator, Clinical Cardiology and Cardiovascular Interventions, Auctores Publishing LLC. I appreciate the journal (JCCI) editorial office support, the entire team leads were always ready to help, not only on technical front but also on thorough process. Also, I should thank dear reviewers’ attention to detail and creative approach to teach me and bring new insights by their comments. Surely, more discussions and introduction of other hemodynamic devices would provide better prevention and management of shock states. Your efforts and dedication in presenting educational materials in this journal are commendable. Best wishes from, Farahnaz Fallahian.
Dear Ashley Rosa, Editorial Coordinator of the journal - Psychology and Mental Health Care. " The process of obtaining publication of my article in the Psychology and Mental Health Journal was positive in all areas. The peer review process resulted in a number of valuable comments, the editorial process was collaborative and timely, and the quality of this journal has been quickly noticed, resulting in alternative journals contacting me to publish with them." Warm regards, Susan Anne Smith, PhD. Australian Breastfeeding Association.
Dear Jessica, and the super professional team of the ‘Clinical Cardiology and Cardiovascular Interventions’ I am sincerely grateful to the coordinated work of the journal team for the no problem with the submission of my manuscript: “Cardiometabolic Disorders in A Pregnant Woman with Severe Preeclampsia on the Background of Morbid Obesity (Case Report).” The review process by 5 experts was fast, and the comments were professional, which made it more specific and academic, and the process of publication and presentation of the article was excellent. I recommend that my colleagues publish articles in this journal, and I am interested in further scientific cooperation. Sincerely and best wishes, Dr. Oleg Golyanovskiy.
To Dear Erin Aust – Editorial Coordinator of Journal of General Medicine and Clinical Practice! I declare that I am absolutely satisfied with your work carried out with great competence in following the manuscript during the various stages from its receipt, during the revision process to the final acceptance for publication. Thank Prof. Elvira Farina
My article, titled 'No Way Out of the Smartphone Epidemic Without Considering the Insights of Brain Research,' has been republished in the International Journal of Clinical Case Reports and Reviews. The review process was seamless and professional, with the editors being both friendly and supportive. I am deeply grateful for their efforts.
We found the peer review process quick and positive in its input. The support from the editorial officer has been very agile, always with the intention of improving the article and taking into account our subsequent corrections.
Dear Jessica Magne, with gratitude for the joint work. Fast process of receiving and processing the submitted scientific materials in “Clinical Cardiology and Cardiovascular Interventions”. High level of competence of the editors with clear and correct recommendations and ideas for enriching the article.
I thank the ‘Journal of Clinical Research and Reports’ for accepting this article for publication. This is a rigorously peer reviewed journal which is on all major global scientific data bases. I note the review process was prompt, thorough and professionally critical. It gave us an insight into a number of important scientific/statistical issues. The review prompted us to review the relevant literature again and look at the limitations of the study. The peer reviewers were open, clear in the instructions and the editorial team was very prompt in their communication. This journal certainly publishes quality research articles. I would recommend the journal for any future publications.
"I am grateful for the opportunity of contributing to [International Journal of Clinical Case Reports and Reviews] and for the rigorous review process that enhances the quality of research published in your esteemed journal. I sincerely appreciate the time and effort of your team who have dedicatedly helped me in improvising changes and modifying my manuscript. The insightful comments and constructive feedback provided have been invaluable in refining and strengthening my work".
To Dear Erin Aust, I would like to express my heartfelt appreciation for the opportunity to have my work published in this esteemed journal. The entire publication process was smooth and well-organized, and I am extremely satisfied with the final result. The Editorial Team demonstrated the utmost professionalism, providing prompt and insightful feedback throughout the review process. Their clear communication and constructive suggestions were invaluable in enhancing my manuscript, and their meticulous attention to detail and dedication to quality are truly commendable. Additionally, the support from the Editorial Office was exceptional. From the initial submission to the final publication, I was guided through every step of the process with great care and professionalism. The team's responsiveness and assistance made the entire experience both easy and stress-free. I am also deeply impressed by the quality and reputation of the journal. It is an honor to have my research featured in such a respected publication, and I am confident that it will make a meaningful contribution to the field.
I would like to express my sincere gratitude for the support and efficiency provided by the editorial office throughout the publication process of my article, “Delayed Vulvar Metastases from Rectal Carcinoma: A Case Report.” I greatly appreciate the assistance and guidance I received from your team, which made the entire process smooth and efficient. The peer review process was thorough and constructive, contributing to the overall quality of the final article. I am very grateful for the high level of professionalism and commitment shown by the editorial staff, and I look forward to maintaining a long-term collaboration with the International Journal of Clinical Case Reports and Reviews.
Dear Agrippa Hilda- Editorial Coordinator of Journal of Neuroscience and Neurological Surgery, "The peer review process was very quick and of high quality, which can also be seen in the articles in the journal. The collaboration with the editorial office was very good."
I would like to offer my testimony in the support. I have received through the peer review process and support the editorial office where they are to support young authors like me, encourage them to publish their work in your esteemed journals, and globalize and share knowledge globally. I really appreciate your journal, peer review, and editorial office.
My experience publishing in International Journal of Clinical Case Reports and Reviews was exceptional. I Come forth to Provide a Testimonial Covering the Peer Review Process and the editorial office for the Professional and Impartial Evaluation of the Manuscript.
My experience publishing in Psychology and Mental Health Care was exceptional. The peer review process was rigorous and constructive, with reviewers providing valuable insights that helped enhance the quality of our work. The editorial team was highly supportive and responsive, making the submission process smooth and efficient. The journal's commitment to high standards and academic rigor makes it a respected platform for quality research. I am grateful for the opportunity to publish in such a reputable journal.
My Testimonial Covering as fellowing: Lin-Show Chin. The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews.
Dealing with The Journal of Neurology and Neurological Surgery was very smooth and comprehensive. The office staff took time to address my needs and the response from editors and the office was prompt and fair. I certainly hope to publish with this journal again.Their professionalism is apparent and more than satisfactory. Susan Weiner
Dear Editorial Coordinator of the Journal of Nutrition and Food Processing! "I would like to thank the Journal of Nutrition and Food Processing for including and publishing my article. The peer review process was very quick, movement and precise. The Editorial Board has done an extremely conscientious job with much help, valuable comments and advices. I find the journal very valuable from a professional point of view, thank you very much for allowing me to be part of it and I would like to participate in the future!”
Dear Monica Gissare, - Editorial Coordinator of Nutrition and Food Processing. ¨My testimony with you is truly professional, with a positive response regarding the follow-up of the article and its review, you took into account my qualities and the importance of the topic¨.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, I hope this message finds you well. I want to express my utmost gratitude for your excellent work and for the dedication and speed in the publication process of my article titled "Navigating Innovation: Qualitative Insights on Using Technology for Health Education in Acute Coronary Syndrome Patients." I am very satisfied with the peer review process, the support from the editorial office, and the quality of the journal. I hope we can maintain our scientific relationship in the long term.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
